Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 9/20 | 0.64 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.64 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | MLNR | O43193 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | MMP1 | P03956 | 1/20 | 0.64 |
| ▸ | MPO | P05164 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.64 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.64 |
| ▸ | APEX1 | P27695 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8942128 | 0.88 | PTGS1 (0.55) | PTGS1PTGS2ADORA3CYP19A1KDM4E | |
| SCHEMBL13524349 | 0.84 | PTGS1 (0.65) | PTGS1PTGS2ADORA3CYP19A1KDM4E | |
| SCHEMBL8719438 | 0.81 | PTGS2 (0.68) | PTGS1PTGS2ADORA3CYP19A1KDM4E | |
| SCHEMBL13659014 | 0.80 | PTGS1 (0.61) | PTGS1PTGS2ADORA3CYP19A1KDM4E | |
| SCHEMBL10337745 | 0.80 | PTGS1 (0.61) | PTGS1PTGS2ADORA3CYP19A1KDM4E | |
| SCHEMBL12998566 | 0.80 | PTGS1 (0.61) | PTGS1PTGS2ADORA3CYP19A1KDM4E | |
| SCHEMBL3234161 | 0.80 | LMNA (0.49) | PTGS1PTGS2KDM4EMEN1LMNA | |
| Nimesulide SCHEMBL6763666 | 0.79 | CYP19A1 (0.79) | PTGS1PTGS2ADORA3CYP19A1KDM4E | |
| SCHEMBL30583076 | 0.79 | PTGS1 (0.60) | PTGS1PTGS2ADORA3CYP19A1KDM4E | |
| SCHEMBL9657535 | 0.79 | PTGS1 (0.60) | PTGS1PTGS2ADORA3CYP19A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12281133-B2 | Hyaluronan conjugate | AIHOL CORPORATION (US) | 2025-04-22 | — | — | US | disclosed |
| CN-118773142-A | Hybridoma cell strain secreting nimex Shu Lishan clone antibody and application thereof | 江南大学 | 2024-10-15 | — | — | CN | disclosed |
| CN-115209904-B | Hyaluronic acid complex and use of hyaluronic acid complex | 爱禾公司 | 2024-09-10 | — | — | CN | disclosed |
| EP-4355314-A1 | USES OF HYALURONAN CONJUGATE | Aihol Corporation (US) | 2024-04-24 | — | — | EP | disclosed |
| CN-116782906-A | Use of hyaluronic acid complexes | 爱禾公司 | 2023-09-19 | — | — | CN | disclosed |
| EP-4217412-A1 | WASTE MITIGATION METHODS AND MATERIALS | Finite Research Ltd (GB) | 2023-08-02 | — | — | EP | disclosed |
| US-20230227490-A1 | HYALURONAN CONJUGATE | AIHOL CORPORATION (US) | 2023-07-20 | — | — | US | disclosed |
| US-11643431-B2 | Uses of hyaluronan conjugate | AIHOL CORPORATION (US) | 2023-05-09 | — | — | US | disclosed |
| EP-4146231-A1 | USES OF HYALURONAN CONJUGATE | Aihol Corporation (US) | 2023-03-15 | — | — | EP | disclosed |
| WO-2022266472-A1 | USES OF HYALURONAN CONJUGATE | AIHOL CORPORATION (US) | 2022-12-22 | — | — | WO | disclosed |
| US-20220401567-A1 | USES OF HYALURONAN CONJUGATE | AIHOL CORPORATION (US) | 2022-12-22 | — | — | US | disclosed |
| CN-115353667-A | Method and material for reducing waste | 李蓁蓁 | 2022-11-18 | — | — | CN | disclosed |
| CN-115209904-A | Hyaluronic acid complex and use of hyaluronic acid complex | 爱禾公司 | 2022-10-18 | — | — | CN | disclosed |
| WO-2022023916-A1 | WASTE MITIGATION METHODS AND MATERIALS | LI, Zhenzhen (CN) | 2022-02-03 | — | — | WO | disclosed |
| US-20220025119-A1 | WASTE MITIGATION METHODS AND MATERIALS | LI SHENSHEN (US) | 2022-01-27 | — | — | US | disclosed |
| WO-2021252513-A1 | USES OF HYALURONAN CONJUGATE | AIHOL CORPORATION (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20210380625-A1 | USES OF HYALURONAN CONJUGATE | AIHOL CORPORATION (US) | 2021-12-09 | — | — | US | disclosed |
| WO-2013020600-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A DRUG CONTAINING AT LEAST ONE TOXICOPHORE FUNCTION AND N-ACETYL-L-CYSTEINE | CROSS SA (CH) | 2013-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380625-A1 | USES OF HYALURONAN CONJUGATE | CD44, ENGASE, HEXD | PTGS1 1041/4885PTGS2 1851/4885ADORA3 947/4885 |
| US-12281133-B2 | Hyaluronan conjugate | CD44, HEXD, FUT5 | PTGS1 2009/4885PTGS2 2776/4885ADORA3 1445/4885 |
| US-11643431-B2 | Uses of hyaluronan conjugate | CD44, ENGASE, HEXD | PTGS1 1041/4885PTGS2 1851/4885ADORA3 947/4885 |
| US-20220401567-A1 | USES OF HYALURONAN CONJUGATE | CD44, FUT5, FUT6 | PTGS1 2672/4885PTGS2 3226/4885ADORA3 1391/4885 |
| US-20230227490-A1 | HYALURONAN CONJUGATE | CD44, HEXD, FUT5 | PTGS1 2009/4885PTGS2 2776/4885ADORA3 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.